Progress against cancer doesn’t always arrive as headlines. Often, it shows up quietly in longer lives, better tolerability, ...

Adam Kittai, MD, breaks down the evolving landscape of CLL sequencing—from venetoclax retreatment to triplet regimens. As he ...

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of ...

Immunoglobulin replacement therapy in CLL patients does not reduce serious infection risk, despite increased usage over 14 years. The study found higher infection rates during immunoglobulin therapy ...

Jaypirca showed higher overall response rates than Imbruvica in both treatment-naive and relapsed/refractory CLL/SLL populations. Progression-free survival trends favored Jaypirca, especially in ...

Pirtobrutinib, a highly selective, noncovalent Bruton’s tyrosine kinase inhibitor (BTKi), shows substantial improvements in progression-free survival over the chemotherapy regimen of bendamustine plus ...

Treatment with so-called BTK inhibitors has improved the prognosis for people with chronic lymphocytic leukemia (CLL). At the same time, these drugs affect the immune system and may cause side effects ...

Pirtobrutinib was associated with a statistically significant improvement in PFS compared with bendamustine plus rituximab therapy. Topline data were announced from a phase 3 trial evaluating ...

Readouts in rare blood cancers like myelofibrosis, WM and CLL are attracting keen interest at this year’s ASCO conference.

Copiktra (duvelisib) is a type of cancer treatment for certain people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). CLL and SLL are slow-growing cancers that affect a ...